Contact
Please use this form to send email to PR contact of this press release:
Ultragenyx Announces Topline Data from Phase 2 UX007 Glucose Transporter Type-1 Deficiency Syndrome Seizure Study
TO:
Please use this form to send email to PR contact of this press release:
Ultragenyx Announces Topline Data from Phase 2 UX007 Glucose Transporter Type-1 Deficiency Syndrome Seizure Study
TO: